Skip to main content
. 2016 Feb 23;89(1060):20150635. doi: 10.1259/bjr.20150635

Table 4.

Comparisons of doses to the target between the control and test plans in different patient groups

Dose–volume parameters Group 1 (n = 15)
 Group 2 (n = 15)
 Group 3 (n = 20)
Control plan (mean ± SD) Test plan (mean ± SD) p-value Control plan (mean ± SD) Test plan (mean ± SD) p-value Control plan (mean ± SD) Test plan (mean ± SD) p-value
PTVnx
 V100 (%)
 96.47 ± 1.79
 95.91 ± 1.73
 0.024
 95.89 ± 1.51
 95.70 ± 1.56
 0.267
 95.71 ± 1.28
 95.45 ± 1.14
 0.825
 V93 (%)
 100.00 ± 0.00
 100.00 ± 0.00
 1.000
 99.95 ± 0.13
 99.96 ± 0.14
 0.655
 99.92 ± 0.23
 99.93 ± 0.20
 0.109
 Dmean (Gy)
 71.71 ± 0.54
 71.66 ± 0.61
 0.609
 71.82 ± 0.51
 71.85 ± 0.68
 0.910
 72.04 ± 0.48
 72.11 ± 0.42
 0.232
PTVnd
 V100 (%)
 98.15 ± 1.75
 98.04 ± 1.95
 0.666
 97.45 ± 2.07
 97.32 ± 1.73
 0.690
 97.21 ± 2.02
 97.29 ± 2.22
 0.825
 V93 (%)
 100.00 ± 0.00
 100.00 ± 0.00
 1.000
 99.81 ± 0.60
 99.80 ± 0.63
 1.000
 99.87 ± 0.27
 99.85 ± 0.30
 0.024
 Dmean (Gy)
 68.61 ± 1.34
 68.66 ± 1.40
 0.784
 68.41 ± 1.07
 68.58 ± 1.56
 0.790
 69.08 ± 1.19
 69.29 ± 1.31
 0.027
PTV1
 V100 (%)
 95.06 ± 1.02
 95.62 ± 0.84
 0.016
 95.48 ± 1.07
 95.71 ± 0.87
 0.184
 94.81 ± 1.25
 95.23 ± 1.36
 0.015
 V93 (%)
 99.90 ± 0.21
 99.92 ± 0.18
 0.192
 99.84 ± 0.29
 99.82 ± 0.32
 0.859
 99.52 ± 0.55
 99.50 ± 0.57
 0.568
 Dmean (Gy)
 64.60 ± 1.04
 64.66 ± 1.11
 0.427
 65.08 ± 0.91
 65.10 ± 1.01
 0.865
 65.99 ± 0.93
 66.12 ± 0.94
 0.030
Dmax (Gy)
 74.54 ± 0.91
 74.46 ± 1.01
 0.766
 74.54 ± 0.80
 74.61 ± 1.14
 0.688
 75.09 ± 0.55
 75.33 ± 0.61
 0.029
CI
 0.87 ± 0.03
 0.87 ± 0.03
 1.000
 0.86 ± 0.04
 0.86 ± 0.04
 1.000
 0.87 ± 0.02
 0.87 ± 0.02
 1.000
HI 0.05 ± 0.01 0.05 ± 0.01 0.880 0.06 ± 0.02 0.06 ± 0.02 0.609 0.07 ± 0.02 0.08 ± 0.02 0.017

CI, conformity index; Dmax, maximum dose; Dmean, mean dose; HI, homogeneity index; PTV1, planning target volume 1; PTVnd, planning target volume of lymph nodes; PTVnx, planning target volume at nasopharynx; SD, standard deviation.